LX-2021

N/A

Report date: 2025/02/08 15:01:10

Base Information

Drug NameLX-2021
Drug Alias NameARVC CX43 (LEXEO Therapeutics)LX-2021
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGap junction alpha-1 protein gene transference
TargetsGap junction alpha-1 protein
Therapy Area/IndicationsCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStelios Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLexeo Therapeutics IncLEXEO Therapeutics
Inactive CompaniesN/A
Active IndicationsCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A